A股異動 | 九安醫療(002432.SZ)再度大漲近7% 美國ACC已支付2116.8萬人份iHealth試劑盒產品貨款共計1.08億美元
格隆匯2月10日丨九安醫療(002432.SZ)再度大漲近7%,報65.87元,總市值315億元,開盤不到半小時成交額已達25億元。九安醫療公吿,公司美國子公司已經就iHealth試劑盒產品向合同對手方交貨共計1.05億人份,美國ACC於當地時間2022年2月7日向公司美國子公司就其中的2116.80萬人份試劑盒產品支付貨款共計1.08億美元,上述貨款現已到賬,約合人民幣6.87億元。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.